CagriSema Research Guide

Full name: CagriSema (Cagrilintide + Semaglutide)

A fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) targeting complementary appetite pathways for enhanced weight loss.

How CagriSema Works

Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression.

Dosing Protocol

• Typical dose: Cagrilintide 2.4mg + Semaglutide 2.4mg
• Frequency: Once weekly
• Duration: Ongoing
• Route: Subcutaneous

Reported Benefits

• Enhanced weight loss vs monotherapy
• Dual appetite suppression
• Convenient single injection
• Improved metabolic parameters
• Potential 20-25% weight loss

Potential Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Injection site reactions

Research Citations

1. Phase 2 CagriSema combination for obesity (2023) - CagriSema achieved 15.6% weight loss at 32 weeks vs 5.1% cagrilintide alone and 8.1% semaglutide alone.
2. Amylin-GLP-1 combination approaches (2022) - Dual-pathway targeting showed additive appetite suppression in neuroimaging studies.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• Survodutide - Full Profile

View full CagriSema profile with 3D molecule viewer →